Teva Pharmaceutical Industries Limited

NYSE:TEVA Stok Raporu

Piyasa değeri: US$41.2b

Teva Pharmaceutical Industries Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Teva Pharmaceutical Industries kazanç ve gelirin sırasıyla yıllık 9.1% ve 2.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 10.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 22.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

9.1%

Kazanç büyüme oranı

10.80%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi12.8%
Gelir büyüme oranı2.4%
Gelecekteki özkaynak getirisi22.10%
Analist kapsamı

Good

Son güncelleme30 Apr 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Teva Pharmaceutical Industries (TEVA): The Generic Giant Pivots Toward an Innovative Supercycle

Teva Pharmaceutical Industries Ltd. (TEVA) , the global vanguard of generic medicine and a rising force in innovative biopharmaceuticals, enters the weekend of Sunday, April 26, 2026 , in a state of high-conviction growth.

TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal

Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.

Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy

Apr 14

Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine

Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?

TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal

Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.

TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook

Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.

TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook

Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.

TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook

Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.

TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating

Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.

TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook

Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.

TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally

Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.

TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins

Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.

TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches

Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.

We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative

Nov 13
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Nov 12
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears

Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.

Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries

Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.

Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand

As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.

Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Has A Meaningful Debt Burden

Jul 14
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Has A Meaningful Debt Burden

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Held Back By Insufficient Growth Even After Shares Climb 26%

May 17
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Held Back By Insufficient Growth Even After Shares Climb 26%
User avatar

Generics And Biosimilars Pipeline And Expansion Will Define Progress

The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.

Teva Pharmaceutical: A Risky Bet With Potential Upside

Feb 28

Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity

Jan 30

Duvakitug And Teva's Growth: A Game Changer In Pharma

Dec 27

Teva: Becoming Increasingly Solid, But No Longer Undervalued

Dec 04

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 23

Cheap Teva Stock Should Reward Patient Investors

Sep 09

Teva's Transformation: From Generics Leader To Branded Drug Innovator

Aug 14

Teva's Q2 Outlook: Key Developments In Biosimilars And Pipeline Drugs

Jul 26

Teva Pharmaceutical: Buy This Bargain Before It's Gone

Jun 07

Kazanç ve Gelir Büyüme Tahminleri

NYSE:TEVA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/202817,9322,3933,7883,0098
12/31/202717,3082,5193,0232,57710
12/31/202616,5561,8252,2151,46810
3/31/202617,3491,5651,1721,714N/A
12/31/202517,2581,4101,1481,649N/A
9/30/202516,7767135781,066N/A
6/30/202516,628-1578901,390N/A
3/31/202516,616-1,2867651,266N/A
12/31/202416,544-1,6397491,247N/A
9/30/202416,772-9591,3681,856N/A
6/30/202416,290-4536791,168N/A
3/31/202416,004-4788781,389N/A
12/31/202315,846-5598421,368N/A
9/30/202315,273-2,3366081,157N/A
6/30/202315,017-2,3501,1731,695N/A
3/31/202314,925-1,7119641,494N/A
12/31/202214,925-2,4461,0421,590N/A
9/30/202215,141-1,2915141,073N/A
6/30/202215,433-1,0544761,059N/A
3/31/202215,557-6155851,154N/A
12/31/202115,878417236798N/A
9/30/202116,23172688673N/A
6/30/202116,324-3,915-131451N/A
3/31/202116,284-3,982-94506N/A
12/31/202016,659-3,9906381,216N/A
9/30/202016,673-4,0319021,423N/A
6/30/202016,78848941,441N/A
3/31/202017,095-825413941N/A
12/31/201916,887-999N/A748N/A
9/30/201916,396-4,048N/A577N/A
6/30/201916,831-4,007N/A673N/A
3/31/201917,355-3,559N/A1,062N/A
12/31/201818,271-2,399N/A2,446N/A
9/30/201819,693-11,059N/A2,938N/A
6/30/201820,781-10,256N/A3,312N/A
3/31/201821,800-16,050N/A3,585N/A
12/31/201721,853-16,525N/A2,225N/A
9/30/201723,479-5,963N/A2,791N/A
6/30/201723,425-6,145N/A3,457N/A
3/31/201722,74378N/A3,985N/A
12/31/201621,90368N/A3,890N/A
9/30/201620,2921,591N/A5,415N/A
6/30/201619,5521,346N/A5,047N/A
3/31/201619,4801,697N/A5,564N/A
12/31/201519,6521,573N/A5,542N/A
9/30/201519,9391,775N/A5,679N/A
6/30/201520,1742,548N/A6,010N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: TEVA 'nin tahmini kazanç büyümesi (yıllık 9.1% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: TEVA şirketinin kazançlarının (yıllık 9.1% ) US pazarından (yıllık 15.8% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: TEVA şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: TEVA şirketinin gelirinin (yıllık 2.4% ) US pazarından (yıllık 11% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: TEVA şirketinin gelirinin (yıllık 2.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: TEVA 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 22.1 %)

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/04/30 04:55
Gün Sonu Hisse Fiyatı2026/04/30 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Teva Pharmaceutical Industries Limited 46 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Jasper HellwegArgus Research Company
Balaji PrasadBarclays
Glen SantangeloBarclays